Navigation Links
Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Date:12/3/2010

nduced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline like potency in the treatment of relapsed/refractory aggressive lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory aggressive NHL and/or other tumors as determined by the FDA and/or the EMA, that the FDA may not accept CTI's proposed design for the protocol of CTI's PIX306 clinical trial and/or may request additional clinical trials, that if CTI conducts an additional clinical trial, it may not demonstrate the safety and effectiveness of pixantrone, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI may not initiate a new clinical trial for pixantrone in 2010, that CTI cannot predict the outcome of the formal dispute resolution process, that the FDA may not make its decision on the appeal in the first quart
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Medina Medical announced today that Mr. ... the Board of Directors on August 18, 2014. Mr. ... commercialization experience, including over a decade of direct experience ... a Partner of the medical device incubator The Foundry, ... Foundry start-ups. Mr. Engelson previously served as the Chief ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... -- Research and Markets has announced the ... of Pharmaceutical Equipment Market in China, 2014-2018" report ... Trend Forecast of Pharmaceutical Equipment Market in ... pharmaceutical equipment industry in the aspects of ... business performance of domestic major enterprises, as well as ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... , , LAKE FOREST, Ill. ... leading developer and manufacturer of injectable pharmaceuticals announced today ... of Corvert ® from Pfizer Inc. , (Logo: ... Injection further demonstrates Bioniche Pharma,s continued growth and dedication ...
... CHARLOTTESVILLE, Virginia , January ... and Drug Administration (FDA) has licensed its,technology platform to help ... harmful side effects. , The FDA,s ... Research (CDER), will test the use of Biovista,s Adverse Event,Analysis ...
Cached Medicine Technology:Bioniche Pharma Launches Ibutilide Fumarate Injection 2Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative 2
(Date:8/30/2014)... "My wife suffered neck, back and spine injuries ... of two inventors from Bethel, Alaska. "The whiplash contributed ... area. She tried other pillows to little avail. The ... comfort and providing extra sleep." , They created a ... head, neck and back comfortably. This enables the user ...
(Date:8/30/2014)... 30, 2014 "My niece developed a ... at any moment, her fever might get worse," said ... me well aware of how she was doing, I ... ALARM to continuously monitor a child's temperature. The unit ... This ensures that prompt medical care can be given, ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 ... transvaginal mesh lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against ... to sever four cases selected for one of ... issued on August 18, 2014, U.S. District Judge ... West Virginia disagrees with Boston Scientific’s contention that ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become especially ... (a medical problem where the airway collapses during sleep and ... rest they need to face their daily challenges. , ... people in the United States alone have sleep apnea. Of ... those treated, many cannot tolerate their prescribed medical device known ...
(Date:8/30/2014)... August 30, 2014 Top10BestSEOHosting.com is ... researchers have announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... current market. Also, they has announced that Bluehost ... , Hostgator, one of the Top 10 ... of cheap Windows hosting, and it offers rich ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2
... CORONA, Calif., July 25 Watson,Pharmaceuticals, Inc. ... announced today that its subsidiary has commenced commercial,shipment ... the 40mg,strength from its Davie, Florida manufacturing facility. ... of marketing exclusivity for being the,first to file ...
... to benefit ALS Therapy Alliance to be presented at Fenway Park ... ... CVS/pharmacy announced today,that this year it has raised a record-breaking $4.4 ... research. This is,the seventh year of the annual fundraising effort which, to ...
... of New York will present an educational meeting regarding age-related macular ... the Farmingdale Public Library at 116 Merritts Road, Farmingdale, NY 11735, ... and refreshments will be provided. The phone number for pre-registration is ... ...
... at Wake Forest University Baptist Medical Center have disproved ... slows or stunts the immune system,s ability to restore ... of drugs known as the "cocktail." , Hepatitis ... leading to rapid liver damage, according to the Centers ...
... Experience it ... Are you an e-patient?,Studies show that 80 percent ... to Web 2.0, e-patients now have even more ways,to ... learn about,advanced medical technologies. Go to http://SutterHealth.org/annualreport ,and ...
... 24 AMICAS, Inc. (Nasdaq: AMCS ),a leader in ... will report the company,s financial results,for the second quarter ending ... 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... Tuesday, August 5, 2008 -- Call begins ...
Cached Medicine News:Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4Health News:AMICAS Schedules Second Quarter Earnings Call 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: